Efficacy of antiarrhythmic drugs on early arrhythmia recurrences after pulmonary vein isolation for atrial fibrillation

房颤(房颤)射频导管消融(肺静脉隔离)后不久房性快速性心律失常常复发。我们前瞻性地研究了三个月低剂量氟卡胺治疗(150或100毫克/天)对房颤消融后前三个月(主要终点)的任何房性快速性心律失常复发的疗效。消融结束后，患者随机分为氟卡因组(n=62)和对照组(n=)，不给予任何抗心律失常药物治疗。氟卡因组和对照组的主要终点发生率分别为37%和41%(P=0.76)。两组远期心律失常复发率分别为21%和25%，P=0.54。房颤消融后短期小剂量氟卡胺治疗并不能减少早期和晚期心律失常的复发。

Atrial tachyarrhythmias commonly recur shortly after radiofrequency catheter ablation (pulmonary vein isolation) for atrial fibrillation (AF). We prospectively examined the efficacy of three-month low-dose flecainide therapy (150 or 100 mg/day) on the recurrences of any atrial tachyarrhythmias during the first three months after AF ablation (primary endpoint). After the ablation, the patients were randomly assigned to the flecainide group (n=62) or to the control group (n=64) receiving no antiarrhythmic drugs. The rates of primary endpoint was 37% and 41% (P=0.76) in the flecainide and control groups, respectively. Long-term arrhythmia recurrence rates were also not different (21% vs. 25%, P=0.54). Short-term low-dose flecainide therapy after AF ablation did not reduce the early and the late arrhythmia recurrences.